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ABSTRACT
ObjectiveaaBrainstem segmentation has been useful in identifying potential imaging biomarkers for diagnosis and progression 
in atypical parkinsonian syndromes (APS). However, the majority of work has been performed using manual segmentation, 
which is time consuming for large cohorts.
MethodsaaWe investigated brainstem involvement in APS using an automated method. We measured the volume of the me-
dulla, pons, superior cerebellar peduncle (SCP) and midbrain from T1-weighted MRIs in 67 patients and 42 controls. Diagnoses 
were corticobasal syndrome (CBS, n = 14), multiple system atrophy (MSA, n = 16: 8 with parkinsonian syndrome, MSA-P; 8 
with cerebellar syndrome, MSA-C), progressive supranuclear palsy with a Richardson’s syndrome (PSP-RS, n = 12), variant PSP 
(n = 18), and APS not otherwise specified (APS-NOS, n = 7).
ResultsaaAll brainstem regions were smaller in MSA-C (19–42% volume difference, p < 0.0005) and in both PSP groups (18–33%, 
p < 0.0005) than in controls. MSA-P showed lower volumes in all regions except the SCP (15–26%, p < 0.0005). The most affected 
region in MSA-C and MSA-P was the pons (42% and 26%, respectively), while the most affected regions in both the PSP-RS and 
variant PSP groups were the SCP (33% and 23%, respectively) and midbrain (26% and 24%, respectively). The brainstem was less 
affected in CBS, but nonetheless, the pons (14%, p < 0.0005), midbrain (14%, p < 0.0005) and medulla (10%, p = 0.001) were signifi-
cantly smaller in CBS than in controls. The brainstem was unaffected in APS-NOS.
ConclusionaaAutomated methods can accurately quantify the involvement of brainstem structures in APS. This will be impor-
tant in future trials with large patient numbers where manual segmentation is unfeasible.
Key WordsaaBrainstem; Magnetic resonance imaging; Parkinsonian syndromes.
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Progressive supranuclear palsy (PSP),1 corticobasal syndrome 
(CBS)2 and multiple system atrophy (MSA)3 are a group of neu-
rodegenerative disorders characterized as “atypical” parkinso-
nian disorders due to shared features of rigidity and bradykine-
sia and features that are atypical for Parkinson’s disease. These 
additional clinical features include supranuclear gaze palsy and 
frequent falls (PSP), dystonia and apraxia (CBS), and autonom-
ic features and ataxia (MSA), but nonetheless, there are a num-
ber of patients who have overlapping features or who do not 
fulfill the diagnostic criteria for a specific condition (atypical 
parkinsonian syndrome not otherwise specified, APS-NOS).4 
Accurate diagnosis is particularly challenging early in the disease 
course.
For all these conditions, there are currently no curative treat-
ments, and patients usually do not respond as well to levodopa 
therapy as those with idiopathic Parkinson’s disease. However, 
potential disease-modifying therapies are in development; there-
fore, it is critical to develop improved methods for diagnosing 
these conditions as early as possible and tracking their progres-
sion to inform the design of treatment trials.
Brainstem segmentation has been useful in identifying po-
tential imaging biomarkers for both diagnosis and progression 
in parkinsonian disorders.5 However, the majority of work has 
been performed using either qualitative measures (such as vi-
sual assessment) or manual segmentation, which is time con-
suming for large cohorts. Here, we investigated differential in-
volvement in the brainstem in atypical parkinsonism using a 
customized automated segmentation tool.
MATERIALS & METHODS
As part of the University College London (UCL) arm of the 
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Mul-
tiple System Atrophy Longitudinal (PROSPECT) study and the 
University College London Longitudinal Investigation of FTD 
(UCL LIFTD) study, we recruited a consecutive series of patients 
with a diagnosis of atypical parkinsonism, including those with 
a T1-weighted MRI scan passing standard quality control pro-
tocols.
A total of 67 patients were identified. Diagnoses in the patient 
group were CBS (n = 14),2 MSA (n = 16: 8 with parkinsonian 
syndrome, MSA-P; 8 with cerebellar syndrome, MSA-C),3 PSP 
with a Richardson’s syndrome (PSP-RS, n = 12), variant PSP (n = 
18: 7 with predominant CBS, PSP-CBS; 3 with predominant par-
kinsonism, PSP-P; 3 with predominant frontal presentation, PSP-
F; 3 with predominant speech/language disorder, PSP-SL; 2 with 
progressive gait freezing, PSP-PGF)1 and APS-NOS (n = 7).4 For-
ty-two cognitively normal subjects enrolled in the same studies, 
with a similar age as the patients and with a usable volumetric 
T1-weighted MRI, were identified as controls. The study was ap-
proved by the local ethics committee (14/LO/1575 and 16/LO/ 
0465), and written informed consent was obtained from all par-
ticipants.
No significant age difference was seen between the patient 
group and controls [patients: 67.1 (9.5) years, controls: 65.3 (7.4); 
p = 0.279, t-test]. However, there was a significant difference in 
gender distribution (patients: 63% male, controls: 43% male; p = 
0.043, chi-squared test). In the clinical groups, there was no dif-
ference in gender (p = 0.089, chi-squared test), but there was a 
significant difference in age, with the MSA-P group being the 
youngest [59.0 (10.8) years] and the APS-NOS and variant PSP 
groups being the oldest [72.5 (8.9) and 74.7 (5.5) years, respec-
tively]. Disease duration was also different (p = 0.006, ANOVA), 
with those in the PSP-RS group having the shortest disease du-
ration [2.7 (1.1) years] and those in the variant PSP group hav-
ing the longest disease duration [5.7 (2.1) years] (Table 1).
T1-weighted MRI scans were acquired with a 3T Siemens 
scanner (Siemens, Erlangen, Germany): after 9 scans, the scan-
ner was upgraded from a Trio (TR = 2,200 ms, TI = 900 ms, TE = 
2.9 ms, acquisition matrix = 256 × 256, spatial resolution = 1.1 
mm, acquisition plane = sagittal) to a Prisma (TR = 2,000 ms, TI = 
850 ms, TE = 2.93 ms, acquisition matrix = 256 × 256, spatial 
resolution = 1.1 mm, acquisition plane=sagittal). Volumetric MRI 
scans were first bias field corrected and whole-brain parcellated 
using the geodesic information flow (GIF) algorithm,6 which is 
based on atlas propagation and label fusion. The volumes of the 
whole brainstem and medulla, pons, superior cerebellar pedun-
cle (SCP) and midbrain (Figure 1) were subsequently segmented 
using a customized version of the module available in FreeSurf-
er (https://surfer.nmr.mgh.harvard.edu/fswiki/BrainstemSub-
structures)7 to accept the GIF parcellation as input for FreeSurfer. 
Volumes were expressed as a percentage of the total intracranial 
volume (TIV), computed with SPM12 v6470 (Statistical Para-
metric Mapping, Wellcome Trust Centre for Neuroimaging, Lon-
don, UK) running under MATLAB R2014b (Math Works, Natick, 
MA, USA).8 All segmentations were visually checked for quality.
Statistical analyses were performed on the volumetric mea-
sures in SPSS software (IBM Corp., Armonk, NY, USA) v22.0. 
Groups were compared using an ANOVA test adjusting for scan-
ner type, TIV, gender and age. The results were corrected for 
multiple comparisons (Bonferroni’s correction) at p < 0.0045. 
To assess the accuracy of the brainstem volume in discriminat-
ing between different diagnoses, we performed a receiver op-
erating characteristic analysis.
RESULTS
All brainstem regions were smaller in the MSA-C group (19–
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42% volume difference, p < 0.0005) and in both PSP groups (18–
33%, p < 0.0005) than in the control group (Table 1 and 2, Fig-
ure 2). The MSA-P group showed lower volumes in all regions 
except the SCP (15–26%, p < 0.0005). The most affected region 
in the MSA-C and MSA-P groups was the pons (42% and 26%, 
respectively), while the most affected regions in both the PSP-
RS and variant PSP groups were the SCP (33% and 23%, respec-
tively) and midbrain (26% and 24%, respectively). The brainstem 
was less affected in the CBS group, but nonetheless, the pons 
(14%, p < 0.0005), midbrain (14%, p < 0.0005) and medulla (10%, 
p = 0.001) were significantly smaller in the CBS group than in the 
control group. The APS-NOS group did not show any signifi-
cant differences from the control group.
When comparing the volumes between the clinical groups, 
the pons was smaller in the MSA-C group than in all the other 
groups (41% vs. the APS-NOS group; 33–42% vs. the CBS and 
both PSP groups; 25% vs. the MSA-P group). The MSA-P group 
showed a smaller pons than APS-NOS group (25%, p < 0.0005). 
Both the PSP-RS and variant PSP groups showed a smaller mid-
brain than the APS-NOS group (18–21%, p < 0.0005), and in the 
PSP-RS group, the midbrain and SCP were smaller than those 
in the CBS group (14% and 25%, p < 0.002). In the PSP-RS and 
variant PSP groups, the pons was smaller than that in the APS-
NOS group (17%, p < 0.002), and in the PSP-RS group, the SCP 
and medulla were smaller than those in the APS-NOS group 
(30% and 15%, respectively, p < 0.001), while the MSA-C group 
showed a smaller SCP than the CBS and APS-NOS groups (26–
31%, p < 0.002) and a smaller midbrain than the APS-NOS group 
(15%, p = 0.001) (Table 1 and 2).
We also performed a subanalysis comparing the individual 
variant PSP syndromes with the control group. Although the num-
bers are small in these groups, nonetheless, the midbrain was 
significantly smaller in almost all variant groups (except for the 
PSP-PGF group) than in the control group (22–27%, p < 0.0005). 
Other significant differences in the brainstem measures were 
found in the PSP-P and PSP-CBS groups, where a significantly 
smaller pons was found than in the control group (22–24%, p = 
0.002), together with a smaller medulla in the PSP-CBS group 
than in the control group (24%, p < 0.0005) (Supplementary Ta-
ble 1 in the online-only Data Supplement).
The brainstem volumes provided a high level of accuracy in 
their ability to discriminate between patients and controls, es-
pecially for the midbrain in the PSP-RS and variant PSP groups 
Figure 1. Example of brainstem segmentation mapped to the T1-
weighted ICBM152 2009c Nonlinear Symmetric 1 × 1 × 1 mm tem-
plate (McConnell Brain Imaging Centre, Montreal Neurological In-






Table 1. Demographic, clinical and volumetric measures of the brainstem in patients and controls




(years) Medulla Pons SCP Midbrain
Whole 
brainstem
Control 42 65.3 (7.4) 18 (43) - 0.37 (0.03) 1.06 (0.09) 0.02 (0.00) 0.44 (0.03) 1.88 (0.14)
APS-NOS 7 72.5 (8.9) 3 (43) 4.4 (1.8) 0.34 (0.02) 1.04 (0.16) 0.02 (0.00) 0.42 (0.06) 1.81 (0.23)
CBS 14 64.3 (8.2) 7 (50) 5.0 (2.7) 0.33 (0.03) 0.91 (0.11) 0.01 (0.00) 0.38 (0.05) 1.64 (0.19)
MSA
MSA-C 8 62.3 (8.1) 6 (75) 4.3 (2.9) 0.30 (0.03) 0.61 (0.17) 0.01 (0.00) 0.35 (0.04) 1.27 (0.23)
MSA-P 8 59.0 (10.8) 6 (75) 4.2 (1.5) 0.31 (0.03) 0.78 (0.16) 0.01 (0.00) 0.36 (0.02) 1.47 (0.19)
PSP-RS 12 64.6 (7.8) 10 (83) 2.7 (1.1) 0.29 (0.04) 0.86 (0.08) 0.01 (0.00) 0.33 (0.03) 1.50 (0.14)
Variant PSP 18 74.7 (5.5) 10 (56) 5.7 (2.1) 0.30 (0.04) 0.86 (0.13) 0.01 (0.00) 0.34 (0.05) 1.51 (0.22)
Subtypes of variant PSP
PSP-CBS 7 77.6 (2.9) 3 (43) 5.1 (1.8) 0.28 (0.04) 0.82 (0.13) 0.01 (0.00) 0.33 (0.05) 1.44 (0.22)
PSP-PGF 2 69.6 (5.4) 2 (100) 5.6 (1.1) 0.34 (0.01) 1.05 (0.06) 0.02 (0.00) 0.41 (0.01) 1.81 (0.06)
PSP-P 3 74.8 (12.4) 2 (67) 5.5 (2.9) 0.31 (0.04) 0.80 (0.11) 0.01 (0.00) 0.32 (0.06) 1.45 (0.22)
PSP-F 3 74.6 (1.7) 2 (67) 5.2 (2.2) 0.31 (0.01) 0.90 (0.09) 0.01 (0.00) 0.34 (0.04) 1.57 (0.14)
PSP-SL 3 72.8 (0.6) 1 (33) 7.8 (2.6) 0.31 (0.04) 0.83 (0.14) 0.01 (0.00) 0.33 (0.06) 1.48 (0.24)
Values represent the mean (standard deviation) of the volumes as a percentage of the total intracranial volume. SCP: superior cerebellar peduncle, 
APS-NOS: atypical parkinsonian syndrome not otherwise specified, CBS: corticobasal syndrome, MSA-C: multiple system atrophy (MSA) with cere-
bellar syndrome, MSA-P: MSA with parkinsonian syndrome, PSP-RS: progressive supranuclear palsy (PSP) with a Richardson’s syndrome, PSP-
CBS: variant PSP with predominant CBS, PSP-PGF: variant PSP with progressive gait freezing, PSP-P: variant PSP with predominant parkinson-




Table 2. Statistical comparisons of the brainstem volumetric measures between patients and controls
Group comparisons  Medulla Pons SCP Midbrain Whole brainstem
Controls
APS-NOS p 0.189 0.903 0.767 0.19 0.546
% 7 2 4 6 4
CBS p 0.001* < 0.0005* 0.08 < 0.0005* < 0.0005*
% 10* 14* 10 14* 13*
MSA-C p < 0.0005* < 0.0005* < 0.0005* < 0.0005* < 0.0005*
% 19* 42* 33* 21* 32*
MSA-P p < 0.0005* < 0.0005* 0.018 < 0.0005* < 0.0005*
% 15* 26* 18 18* 22*
PSP-RS p < 0.0005* < 0.0005* < 0.0005* < 0.0005* < 0.0005*
% 21* 18* 33* 26* 21*
Variant PSP p < 0.0005* < 0.0005* < 0.0005* < 0.0005* < 0.0005*
% 18* 19* 23* 24* 20*
APS-NOS
CBS p 0.281 0.016 0.38 0.027 0.022
% 3 12 6 8 9
MSA-C p 0.006 < 0.0005*   0.001*   0.001* < 0.0005*
% 13 41* 31* 15* 30*
MSA-P p 0.058 < 0.0005* 0.098 0.005 < 0.0005*
% 9 25* 15 13 19*
PSP-RS p   0.001*   0.002* < 0.0005* < 0.0005* < 0.0005*
% 15* 17* 30* 21* 17*
Variant PSP p 0.011   0.001* 0.018 < 0.0005* < 0.0005*
% 12 17* 20 18* 17*
CBS
MSA-C p 0.025 < 0.0005*   0.002* 0.053 < 0.0005*
% 10 33* 26* 8 22*
MSA-P p 0.223 0.014 0.348 0.221 0.033
% 6 14 9 5 10
PSP-RS p 0.006 0.314   0.001*   0.002* 0.058
% 13 5 25* 14* 9
Variant PSP p 0.101 0.436 0.096 0.023 0.184
% 9 6 14 12 8
MSA-C
MSA-P p 0.367   0.004* 0.060 0.538 0.026
% -5 -28* -23 -3 -16
PSP-RS p 0.677 < 0.0005* 0.822 0.253 0.005
% 3 -42* -1 6 -18
Variant PSP p 0.449 < 0.0005* 0.067 0.855   0.001*
% -1 -41* -16 4 -19*
MSA-P
PSP-RS p 0.167 0.115 0.069 0.076 0.711
% 7 -11 18 9 -2
Variant PSP p 0.818 0.091 0.812 0.410 0.371
% 4 -10 6 7 -3
PSP-RS
Variant PSP p 0.182 0.767 0.04 0.298 0.487
% -4 1 -15 -3 -1
p values and percentage volumetric difference between groups are shown with analyses adjusted for age, gender and scanner type. *Significant dif-
ference between groups after correction for multiple comparisons. SCP: superior cerebellar peduncle, APS-NOS: atypical parkinsonian syndrome 
not otherwise specified, CBS: corticobasal syndrome, MSA-C: multiple system atrophy (MSA) with cerebellar syndrome, MSA-P: MSA with parkinso-
nian syndrome, PSP: progressive supranuclear palsy, PSP-RS: PSP with a Richardson’s syndrome.
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Figure 2. Volumes of the superior cerebellar peduncle, midbrain, pons, and medulla as a percentage of controls in (A) atypical parkinsonian 
syndrome not otherwise specified (APS-NOS), (B) corticobasal syndrome (CBS), (C) multiple system atrophy with cerebellar syndrome 
(MSA-C), (D) multiple system atrophy with parkinsonian syndrome (MSA-P), (E) progressive supranuclear palsy with a Richardson’s syn-
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(100% and 98% accuracy, respectively, p < 0.0005), and the 
midbrain and pons in the MSA-C and MSA-P groups (98%, p < 
0.0005) (Table 3). When comparing the disease groups, the best 
discriminators were the pons volume for the comparisons of 
the MSA-C vs. the APS-NOS group (96% accuracy, p = 0.003), 
the MSA-C vs. the CBS group (93%, p = 0.001), and the MSA-C 
vs. the PSP-RS and variant PSP groups (90%, p < 0.003) and the 
midbrain and medulla volumes for the PSP-RS and APS-NOS 
groups (92% and 89%, respectively, p < 0.005) (Table 3).
DISCUSSION
We have shown that with an automated segmentation meth-
od, we are able to accurately quantify the involvement of brain-
stem structures in atypical parkinsonian syndromes. We found 
that in MSA, the disease affects the pons most significantly, with 
this region being significantly smaller in the MSA-C group than 
in all other groups. This finding is in line with previous stud-
ies9-11 and the clinically recognized “hot cross bun” sign typically 
described in MSA, which represents the degeneration of the pons 
and the pontocerebellar fibers.12 Abnormalities in other regions 
of the brainstem have been described in MSA to a lesser extent, 
which is also consistent with our findings here.13-15
We found smaller volumes of the midbrain and the SCP in the 
PSP group. As other studies have shown, PSP is typically char-
acterized by the “hummingbird” sign,5,12,13 indicating atrophy in 
the midbrain (with relative preservation of the pons), together 
with atrophy in the SCP.14,15 Here, we show that the same overall 
pattern of brainstem involvement occurs in those with variant 
PSP (SCP/midbrain > pons/medulla), as is seen with PSP-RS, but 
to a lesser extent.
Compared to the MSA and PSP groups, and as previously re-
ported, the brainstem was less affected in the CBS group. CBS is 
typically characterized by asymmetric atrophy of the frontal and 
parietal cortex, together with the striatum,12 but nonetheless, in-
volvement of the midbrain, pons and medulla can also occur, as 
we have shown here.9,16
Interestingly, none of the regions in the brainstem were affect-
ed in the APS-NOS group. This finding is suggestive that pa-
tients are at an earlier stage of the illness when the characteris-
tic features for a specific diagnosis (both clinical and imaging) 
are not present; that these patients do not have MSA, PSP or CBS 
and instead have another form of parkinsonism, such as Lewy 
body disease; or potentially that APS-NOS is a mixture of differ-
ent disorders at various stages in the disease process.
No prior investigations of automated regional brainstem seg-
mentation in atypical parkinsonian syndromes have reported a 
similar breadth of brainstem structures in all of the disorders and 
variants. Two previous studies showed similar patterns of change 
in MSA-C and MSA-P vs. PSP-RS15 and in MSA (all variants) vs. 
PSP (all variants),17 although differences between patients and 
controls were on average smaller. This is likely to be due to dif-
ferences either in disease stage (with their groups at an earlier 
timepoint) or in methodology [e.g., due to either the different 
MRI scanners used (1.5T in their studies vs. 3T here) or the seg-
mentation technique itself].
With this automated method, we were able to simultaneously 
extract four different volumes of structures in the brainstem and 
quantify specific and differential features in atypical parkinso-
nian syndromes. Automated tools will be important in future tri-
als with large patient numbers where manual segmentation is 
unfeasible. As we adapted the original FreeSurfer pipeline with 
GIF, we can consistently measure with the same pipeline not only 
these four regions in the brainstem but also 160 other brain re-
gions segmented using GIF. Although this study already shows 
the usefulness of brainstem volumes alone in accurately distin-
guishing among these syndromes, future studies will be able to 
test whether combinations of regions of interest improve the dis-
crimination of different atypical parkinsonian syndromes.
The limitations of this study include the lack of pathological 
data and the small number of patients with variant PSP; it would 
be useful to expand the sample and investigate the differences be-
tween the individual variants and PSP-RS. Moreover, the disease 
duration on average was 4.5 years; further studies are needed to 
clarify whether automated segmentation can discriminate di-
agnoses at an earlier stage. Future longitudinal studies that inves-
tigate the rate of atrophy in these brainstem regions will also be 
extremely important, allowing computation of sample sizes and 
helping with the design of clinical trials.
Supplementary Materials
The online-only Data Supplement is available with this article at https://
doi.org/10.14802/jmd.19030.
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Supplementary Table 1. Statistical comparisons of the brainstem volumetric measures between variant PSP and controls
Group comparisons  Medulla Pons SCP Midbrain Whole brainstem
Controls
PSP-CBS p < 0.0005* < 0.0005* 0.005 < 0.0005* < 0.0005*
% 24* 22* 28 26* 24*
PSP-PGF p 0.625 0.995 0.927 0.347 0.779
% 7 1 -4 9 4
PSP-P p 0.014 0.002* 0.031 < 0.0005* < 0.0005*
% 17 24* 24 27* 23*
PSP-F p 0.026 0.051 0.012 < 0.0005* 0.009
% 14 15 31 22* 17
PSP-SL p 0.024 0.006 0.063 < 0.0005* 0.002*
% 17 22 18 25* 22*
p values and percentage volumetric difference between groups are shown with analyses adjusted for age, gender and scanner type. *Significant dif-
ference between groups after correction for multiple comparisons. SCP: superior cerebellar peduncle, PSP-CBS: variant progressive supranuclear 
palsy (PSP) with predominant CBS, PSP-PGF: variant PSP with progressive gait freezing, PSP-P: variant PSP with predominant parkinsonism, 
PSP-F: variant PSP with predominant frontal presentation, PSP-SL: variant PSP with predominant speech/language disorder.
